<table rules="all" width=" 684px" xmlns="urn:hl7-org:v3" xmlns:voc="urn:hl7-org:v3/voc" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 7: Effect of Other Drugs on Voriconazole Pharmacokinetics </caption>
<tbody>
<tr>
<td align="center" colspan="3" stylecode="Lrule Rrule Toprule Botrule" valign="top">
<content stylecode="bold">
<content stylecode="emphasis">[<content stylecode="italics">see <linkhtml href="#dedaa959-69da-4d92-bdf1-60bf27da448b">Clinical Pharmacology
                                                (12.3)</linkhtml>
</content>]</content>
</content>
</td>
</tr>
<tr>
<td align="center" stylecode="Lrule Rrule Toprule Botrule" valign="top">
<paragraph>
<content stylecode="bold">
<content stylecode="emphasis">Drug/Drug Class</content>
</content>
<content stylecode="bold">
<content stylecode="emphasis">
<br/>
                                                  (Mechanism of<br/>
</content>
</content>
<content stylecode="bold">
<content stylecode="emphasis">Interaction by the Drug)</content>
</content>
</paragraph>
</td>
<td align="center" stylecode="Lrule Rrule Toprule Botrule" valign="top">
<paragraph>
<content stylecode="bold">
<content stylecode="emphasis">Voriconazole Plasma<br/>
</content>
</content>
<content stylecode="bold">
<content stylecode="emphasis">Exposure<br/>
</content>
</content>
<content stylecode="bold">
<content stylecode="emphasis">(C<sub>max </sub>and AUC<sub>τ </sub>after<br/>
</content>
</content>
<content stylecode="bold">
<content stylecode="emphasis">200 mg every 12h)</content>
</content>
</paragraph>
</td>
<td align="center" stylecode="Lrule Rrule Toprule Botrule" valign="top">
<paragraph>
<content stylecode="bold">
<content stylecode="emphasis">Recommendations for Voriconazole<br/>
</content>
</content>
<content stylecode="bold">
<content stylecode="emphasis">Dosage Adjustment/Comments</content>
</content>
</paragraph>
</td>
</tr>
<tr>
<td align="left" stylecode="Lrule Rrule Toprule Botrule" valign="top">
<paragraph>Rifampin* and Rifabutin*<br/> (CYP450
                                            Induction)</paragraph>
</td>
<td align="center" stylecode="Lrule Rrule Toprule Botrule" valign="top">
<paragraph>Significantly Reduced</paragraph>
</td>
<td align="center" stylecode="Lrule Rrule Toprule Botrule" valign="top">
<paragraph>
<content stylecode="bold">
<content stylecode="emphasis">Contraindicated</content>
</content>
</paragraph>
</td>
</tr>
<tr>
<td align="left" stylecode="Lrule Rrule Toprule Botrule" valign="top">
<paragraph>Efavirenz (400 mg daily)**<br/>(CYP450 Induction)</paragraph>
<paragraph></paragraph> Efavirenz (300 mg daily)** (CYP450 Induction) </td>
<td align="center" stylecode="Lrule Rrule Toprule Botrule" valign="top">
<paragraph>Significantly Reduced</paragraph>
</td>
<td align="center" stylecode="Lrule Rrule Toprule Botrule" valign="top">
<paragraph>
<content stylecode="bold">Contraindicated </content>
</paragraph>
</td>
</tr>
<tr>
<td align="left" stylecode="Lrule Rrule Toprule Botrule" valign="top">
<paragraph>High-dose Ritonavir<br/> (400 mg every
                                            12h)**<br/> (CYP450 Induction)<br/>   <br/>Low-dose Ritonavir<br/>(100 mg every 12h)**<br/>(CYP450 Induction)</paragraph>
</td>
<td align="center" stylecode="Lrule Rrule Toprule Botrule" valign="top">
<paragraph>Significantly Reduced<br/>   <br/>
                                              <br/>   <br/>Reduced</paragraph>
</td>
<td align="center" stylecode="Lrule Rrule Toprule Botrule" valign="top">
<paragraph>
<content stylecode="bold">
<content stylecode="emphasis">Contraindicated<br/>
</content>
</content>  <br/>
                                              <br/>   <br/>Coadministration of voriconazole and low-dose ritonavir (100 mg every 12h) should be avoided, unless an assessment of the benefit/risk to the patient justifies the use of voriconazole</paragraph>
</td>
</tr>
<tr>
<td align="left" stylecode="Lrule Rrule Toprule Botrule" valign="top">
<paragraph>Carbamazepine<br/> (CYP450 Induction)</paragraph>
</td>
<td align="center" stylecode="Lrule Rrule Toprule Botrule" valign="top">
<paragraph>Not Studied <content stylecode="italics">
<content stylecode="emphasis">In Vivo </content>
</content>or <content stylecode="italics">
<content stylecode="emphasis">In Vitro</content>
</content>, but Likely<br/>
                                             to Result in Significant Reduction</paragraph>
</td>
<td align="center" stylecode="Lrule Rrule Toprule Botrule" valign="top">
<paragraph>
<content stylecode="bold">
<content stylecode="emphasis">Contraindicated</content>
</content>
</paragraph>
</td>
</tr>
<tr>
<td align="left" stylecode="Lrule Rrule Toprule Botrule" valign="top">
<paragraph>Long Acting Barbiturates<br/> (CYP450
                                            Induction)</paragraph>
</td>
<td align="center" stylecode="Lrule Rrule Toprule Botrule" valign="top">
<paragraph>Not Studied <content stylecode="italics">
<content stylecode="emphasis">In Vivo </content>
</content>or <content stylecode="italics">
<content stylecode="emphasis">In Vitro</content>
</content>, but Likely<br/>
                                             to Result in Significant Reduction</paragraph>
</td>
<td align="center" stylecode="Lrule Rrule Toprule Botrule" valign="top">
<paragraph>
<content stylecode="bold">
<content stylecode="emphasis">Contraindicated</content>
</content>
</paragraph>
</td>
</tr>
<tr>
<td align="left" stylecode="Lrule Rrule Toprule Botrule" valign="top">
<paragraph>Phenytoin*<br/> (CYP450 Induction)</paragraph>
</td>
<td align="center" stylecode="Lrule Rrule Toprule Botrule" valign="top">
<paragraph>Significantly Reduced</paragraph>
</td>
<td align="center" stylecode="Lrule Rrule Toprule Botrule" valign="top">
<paragraph>Increase voriconazole maintenance dose from
                                            4 mg/kg to 5 mg/kg IV every 12h or from 200 mg to
                                            400 mg orally every 12h (100 mg to 200 mg orally
                                            every 12h in patients weighing less than 40
                                            kg)</paragraph>
</td>
</tr>
<tr>
<td align="left" stylecode="Lrule Rrule Toprule Botrule" valign="top">
<paragraph>St. John’s Wort<br/>
                                            (CYP450 inducer; P-gp inducer)</paragraph>
</td>
<td align="center" stylecode="Lrule Rrule Toprule Botrule" valign="top">
<paragraph>Significantly Reduced</paragraph>
</td>
<td align="center" stylecode="Lrule Rrule Toprule Botrule" valign="top">
<paragraph>
<content stylecode="bold">
<content stylecode="emphasis">Contraindicated</content>
</content>
</paragraph>
</td>
</tr>
<tr>
<td align="left" stylecode="Lrule Rrule Toprule Botrule" valign="top">
<paragraph>Oral Contraceptives**<br/>
                                            containing ethinyl estradiol and
                                            norethindrone<br/> (CYP2C19 Inhibition)</paragraph>
</td>
<td align="center" stylecode="Lrule Rrule Toprule Botrule" valign="top">
<paragraph>Increased</paragraph>
</td>
<td align="center" stylecode="Lrule Rrule Toprule Botrule" valign="top">
<paragraph>Monitoring for adverse events and toxicity
                                            related to voriconazole is recommended when
                                            coadministered with oral contraceptives</paragraph>
</td>
</tr>
<tr>
<td align="left" stylecode="Lrule Rrule Toprule Botrule" valign="top">
<paragraph>Fluconazole**<br/> (CYP2C9, CYP2C19 and<br/>
                                            CYP3A4 Inhibition)</paragraph>
</td>
<td align="center" stylecode="Lrule Rrule Toprule Botrule" valign="top">
<paragraph>Significantly Increased</paragraph>
</td>
<td align="center" stylecode="Lrule Rrule Toprule Botrule" valign="top">
<paragraph>Avoid concomitant administration of voriconazole
                                            and fluconazole. Monitoring for adverse events and
                                            toxicity related to voriconazole is started within 24 h
                                            after the last dose of fluconazole.</paragraph>
</td>
</tr>
<tr>
<td align="left" stylecode="Lrule Rrule Toprule Botrule" valign="top">
<paragraph>Other HIV Protease<br/> Inhibitors<br/> (CYP3A4
                                            Inhibition)</paragraph>
</td>
<td align="center" stylecode="Lrule Rrule Toprule Botrule" valign="top">
<paragraph>
<content stylecode="italics">
<content stylecode="emphasis">In Vivo
                                            </content>
</content>Studies Showed No Significant
                                            Effects of Indinavir on Voriconazole
                                                Exposure<br/>
<content stylecode="italics">
<content stylecode="emphasis">  <br/> In Vitro
                                                </content>
</content>Studies Demonstrated Potential
                                            for Inhibition of Voriconazole Metabolism (Increased
                                            Plasma Exposure)</paragraph>
</td>
<td align="center" stylecode="Lrule Rrule Toprule Botrule" valign="top">
<paragraph>No dosage adjustment in the voriconazole dosage
                                            needed when coadministered with indinavir<br/>
                                              <br/>    <br/> Frequent monitoring
                                            for adverse events and toxicity related to voriconazole
                                            when coadministered with other HIV protease
                                            inhibitors</paragraph>
</td>
</tr>
<tr>
<td align="left" stylecode="Lrule Rrule Toprule Botrule" valign="top">
<paragraph>Other NNRTIs***<br/>(CYP3A4 Inhibition or CYP450 Induction)</paragraph>
</td>
<td align="center" stylecode="Lrule Rrule Toprule Botrule" valign="top">
<paragraph>
<content stylecode="italics">
<content stylecode="emphasis">In Vitro
                                            </content>
</content>Studies Demonstrated Potential for
                                            Inhibition of Voriconazole Metabolism by Delavirdine and
                                            Other NNRTIs (Increased Plasma Exposure)<br/>  
                                            <br/>A Voriconazole-Efavirenz Drug Interaction Study Demonstrated the Potential for the Metabolism of Voriconazole to be Induced by Efavirenz and Other NNRTIs (Decreased Plasma Exposure)</paragraph>
</td>
<td align="center" stylecode="Lrule Rrule Toprule Botrule" valign="top">
<paragraph>Frequent monitoring for adverse events and
                                            toxicity related to voriconazole<br/>
                                               <br/>   <br/>   <br/>Careful assessment of voriconazole effectiveness</paragraph>
</td>
</tr>
<tr>
<td align="left" colspan="1" stylecode="Lrule Rrule Toprule Botrule" valign="top">Everolimus<br/> (CYP3A4 Inhibition) </td>
<td align="center" colspan="1" stylecode="Lrule Rrule Toprule Botrule" valign="top">Not Studied<content stylecode="italics"> In Vivo</content> or<content stylecode="italics"> In Vitro</content>, but Drug Plasma Exposure Likely to be Increased </td>
<td align="center" colspan="1" stylecode="Lrule Rrule Toprule Botrule" valign="top">Concomitant administration of voriconazole and everolimus is not recommended. </td>
</tr>
<tr>
<td align="left" colspan="3" stylecode="Lrule Rrule Toprule Botrule" valign="top">
<paragraph>*      Results based on
                                                <content stylecode="italics">
<content stylecode="emphasis">in vivo
                                            </content>
</content>clinical studies generally following
                                            repeat oral dosing with 200 mg every 12h voriconazole to
                                            healthy subjects</paragraph>
<paragraph>**    Results based on <content stylecode="italics">
<content stylecode="emphasis">in
                                                  vivo </content>
</content>clinical study following
                                            repeat oral dosing with 400 mg every 12h for 1 day, then
                                            200 mg every 12h for at least 2 days voriconazole to
                                            healthy subjects</paragraph>
<paragraph>*** Non-Nucleoside Reverse Transcriptase Inhibitors</paragraph>
</td>
</tr>
</tbody>
</table>